



Protocol Title: A phase IIIb, open-label, multicentre, international randomised controlled trial of simplified treatment monitoring for 8 weeks glecaprevir (300mg)/pibrentasvir (120mg) in chronic HCV treatment naïve patients without cirrhosis
Protocol No: VHCRP1701

Site Signature and Study Responsibilities Log

Site Name: _____ **Site Code:** _____ **Principal Investigator:** _____

Name of Site Personnel (first and last names)	Signature *	Initials	Start Date (dd/mmm/yyyy)	End Date (dd/mmm/yyyy)	Role (PI, Co-PI, SC, Lab, Lead Pharmacist)	Responsibility Code(s) [^] (indicate codes using codes in attached key)	CV and ICH-GCP certificate filed #	Site PI Authorization ** (initials/date)
							Yes / No	
							Yes / No	
							Yes / No	
							Yes / No	
							Yes / No	
							Yes / No	
							Yes / No	
							Yes / No	
							Yes / No	
							Yes / No	
							Yes / No	

[^] Study Responsibility Codes

- | | | | | |
|---------------------------------|---|--|--|---------------------------|
| 1. Obtaining informed consent | 7. Sign-off eCRF | 12. Collection of blood samples | 16. Monitoring of investigational product (IP) receipt and storage condition | 20. Other (specify) _____ |
| 2. Eligibility determination | 8. Conduct study visit procedures (i.e. randomisation, physical measurements) | 13. Processing and storage of research samples | 17. IP dispensation | 21. Other (specify) _____ |
| 3. Adverse event interpretation | 9. Collection of Fibroscan® data (if available) | 14. eCRF data entry and correction | 18. IP accountability | 22. Other (specify) _____ |
| 4. Prescribe study drug | 10. Adverse event (including SAE) data collection | 15. Maintenance of Investigator Site File | 19. IP destruction/return | |
| 5. Lab Result interpretation | 11. Participant visit scheduling – planning and follow-up | | | |
| 6. SAE Reporting | | | | |

CV must be current within ≤3 years and a copy must be available within the Investigator Site File and sent to Kirby Institute.

* By signing the SMART-C Site Signature and Study Responsibilities Log, you agree that your contact details may be disclosed to AbbVie Inc.

** Each update to the Site Signature and Study Responsibilities Log must be authorised by the PI (initials and date). By authorising, the PI confirms the site personnel completed project specific training prior to performing any study procedures and will operate under the PI's oversight from the Start to End Date.